Pfizer Inc. ($PFE) Stock Forecast: Up 5.0% Today

What is Pfizer Inc.?

Pfizer (PFE): A leading pharmaceutical company known for its innovative drugs and vaccines in a competitive market under regulatory scrutiny.

Why is Pfizer Inc. going up?

PFE stock is up 5.0% on Aug 5, 2025 19:05

• Strong bullish movement attributed to impressive Q2 earnings, beating estimates with significant growth in earnings and revenues.
• Rising sales in oncology drugs like Vyndaqel, Comirnaty, and Paxlovid, as well as cost-cutting measures expected to save billions by 2027, fueled the positive market response.
• Optimism further boosted by the company's raised 2025 EPS guidance and expectations of continued strength in key products like Vyndaqel and Padcev.
• President Trump's ultimatum to lower drug prices may have influenced the overall positive sentiment, potentially benefiting companies like Pfizer in the long run.

PFE Price Chart

PFE Technical Analysis

PFE News

Pfizer Q2 Earnings Beat Estimates, Oncology Drives Top-Line Growth

PFE posts strong Q2 results with earnings up 30% and revenues up 10% year over year, fueled by rising oncology sales and cost cuts.

https://www.zacks.com/stock/news/2668294/pfizer-q2-earnings-beat-estimates-oncology-drives-top-line-growth

Why Is Pfizer Stock Trading Higher Today - Pfizer ( NYSE:PFE )

Pfizer Q2 EPS of $0.78 beat the consensus of $0.57; sales rose 10% Y/Y to $14.7 billion, led by Vyndaqel, Comirnaty, and Paxlovid 2025 EPS guidance raised to $2.90-$3.10; cost cuts expected to save $7.7 billion overall by end of 2027. The next correction is closer than you think.

https://www.benzinga.com/markets/earnings/25/08/46859410/pfizer-cost-cut-initiatives-more-than-offset-tariffs-impact-raises-outlook

Pfizer: How To Earn $500 A Month Ahead Of Q2 Earnings - Pfizer ( NYSE:PFE )

A more conservative goal of $100 monthly dividend income would require 698 shares of Pfizer. An investor would need to own $81,933 worth of Pfizer to generate a monthly dividend income of $500. The market's back, and these 3 income stocks are thriving. See them here→ Pfizer Inc.

https://www.benzinga.com/trading-ideas/dividends/25/08/46824134/how-to-earn-500-a-month-from-pfizer-stock-ahead-of-q2-earnings-2

Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q2 Earnings

PFE eyes Q2 earnings beat as strength in Vyndaqel and Padcev is expected to offset declines from Eliquis, Ibrance and Prevnar.

https://www.zacks.com/stock/news/2649293/buy-sell-or-hold-pfizer-stock-key-tips-ahead-of-q2-earnings

Trump Issues 60 Day Ultimatum To US Pharma Giants To Slash Drug Prices: 'If You Refuse To Step Up We Will...' - AbbVie ( NYSE:ABBV ) , Amgen ( NASDAQ:AMGN )

President Donald Trump has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or face severe consequences. ArrivedBuy shares of homes and vacation rentals for as little as $100. Get Started

https://www.benzinga.com/news/health-care/25/08/46783827/trump-issues-60-day-ultimatum-to-us-pharma-giants-to-slash-drug-prices-if-you-refuse-to-step-up-

Trending Today

Shiba Inu ($SHIB) Crypto Forecast: Down 5.2% Today

XRP ($XRP) Crypto Forecast: Down 5.1% Today

Cardano ($ADA) Crypto Forecast: Down 5.1% Today

Chainlink ($LINK) Crypto Forecast: Down 5.4% Today

Lithia Motors Inc. ($LAD) Stock Forecast: Up 5.1% Today

ONEOK Inc. ($OKE) Stock Forecast: Down 5.0% Today

Transdigm Group Incorporated Inc. ($TDG) Stock Forecast: Down 12.7% Today

Eaton Corporation PLC ($ETN) Stock Forecast: Down 6.7% Today

Palantir Technologies Inc ($PLTR) Stock Forecast: Up 7.2% Today

Pfizer Inc. ($PFE) Stock Forecast: Up 5.0% Today

Pfizer Inc. Price History

04.03.2025 - PFE Stock was down 5.4%

• Despite positive news about expanding the use of its RSV vaccine in the EU and receiving endorsements for its blood cancer combo therapy in the UK, Pfizer (PFE) faced a bearish movement.
• The decline in PFE's stock could be attributed to the overall uncertainty in the pharmaceutical sector due to proposed tariffs on pharma imports, impacting various drug stocks including PFE, MRK, ABBV, and LLY.
• Investors are comparing Pfizer (PFE) with Johnson & Johnson (JNJ) and assessing which drug giant presents a better investment opportunity, leading to a shift in market sentiment towards JNJ over PFE.
• Although Pfizer (PFE) expects improvements in sales and profits in the future, the current market reaction suggests that investors are cautious about the company's performance in the near term, contributing to the bearish movement in its stock price.

15.10.2024 - PFE Stock was down 7.4%

• Pfizer's stock faced significant downward pressure due to concerns surrounding the appointment of a vaccine skeptic to lead the HHS by President-elect Donald Trump.
• This development led to a bearish response in Pfizer's stock price and also impacted other vaccine makers like Moderna, Novavax, and BioNTech.
• Despite the recent decline, there may be an opportunity for investors to consider purchasing Pfizer's stock as it is currently oversold, with analysts increasing earnings estimates, suggesting a potential reversal in the stock's trend soon.

15.10.2024 - PFE Stock was down 6.3%

• Today, Pfizer's stock showed a decline.
• The appointment of a vaccine skeptic, Robert F. Kennedy Jr., by President-elect Donald Trump to lead the HHS has created doubt and uncertainty in the market.
• While Pfizer has seen success in oncology treatments, the focus on vaccine-related news and the prevailing sentiment in the healthcare industry have had a negative impact on the stock.
• Despite indications of bullish options trading towards Pfizer from well-resourced investors, suggesting a possible future upturn, the current market trend remains bearish due to external factors.

29.09.2024 - PFE Stock was down 1.9%

• Despite reporting strong Q3 earnings and revenue beats, the market movement may have been influenced by profit-taking behavior from investors after a period of heightened demand for its COVID products.
• The heightened demand for Paxlovid and expectations of $10 billion in 2024 revenue from COVID products may have already been priced into the stock, leading to a sell-off post-earnings.
• The ongoing proxy battle with activist investor Starboard Value could have added uncertainty and pressure on the stock, contributing to the bearish movement.
• Investors might be closely monitoring Pfizer's non-COVID drug performance and the impact of new and acquired products on the company's future revenue growth, which could influence future market sentiment.

24.01.2025 - PFE Stock was up 0.2%

• The bullish movement in Pfizer's stock today can be attributed to several factors:
• The discovery of a new coronavirus in China has led to a rise in vaccine stocks, including Pfizer, as investors anticipate increased demand for vaccines in response to potential outbreaks.
• Pfizer's decision to discontinue the hemophilia gene therapy Beqvez, which saw low adoption rates, could be viewed positively by investors as the company shifts its focus to more promising products like Hympavzi.
• Despite ongoing investigations into Pfizer's Board of Directors for potential breaches of fiduciary duties, the market seems to be focusing more on the company's product developments and potential for growth in the healthcare sector.

04.01.2025 - PFE Stock was down 2.5%

• Pfizer surpassed earnings and revenue projections in Q4, demonstrating robust performance in its Seagen and COVID-19 product lines. However, despite this, the stock witnessed a downward trend.
• Concerns regarding Pfizer's sustainability of growth momentum, particularly in meeting financial expectations, could have prompted the market's negative response.
• Investors may have anticipated even stronger results from Pfizer, resulting in profit-taking and a temporary decline in stock value.
• The market movement may also be influenced by broader industry trends or sector-specific factors impacting pharmaceutical companies.

15.06.2025 - PFE Stock was down 2.4%

• Pfizer's stock price declined by 1.17% as the market rallied, indicating a bearish trend for the company.
• The announcement of a $1 billion net IRA impact in 2025 due to Medicare Part D changes likely contributed to investor concerns and the negative market reaction.
• The FDA's acceptance of GlaxoSmithKline's filing for expanded use of RSV vaccine in younger adults may have shifted some focus away from Pfizer, impacting its stock performance.
• Moderna's stock surging after receiving full FDA approval for its COVID-19 vaccine in pediatric patients could have also diverted investor attention from Pfizer, potentially leading to the bearish movement in Pfizer's stock price.

05.07.2025 - PFE Stock was up 5.0%

• Strong bullish movement attributed to impressive Q2 earnings, beating estimates with significant growth in earnings and revenues.
• Rising sales in oncology drugs like Vyndaqel, Comirnaty, and Paxlovid, as well as cost-cutting measures expected to save billions by 2027, fueled the positive market response.
• Optimism further boosted by the company's raised 2025 EPS guidance and expectations of continued strength in key products like Vyndaqel and Padcev.
• President Trump's ultimatum to lower drug prices may have influenced the overall positive sentiment, potentially benefiting companies like Pfizer in the long run.

05.07.2025 - PFE Stock was up 5.3%

• Pfizer reported better-than-expected Q2 earnings, with EPS beating consensus and sales rising by 10% year-over-year, driven by key products like Vyndaqel, Comirnaty, and Paxlovid.
• The company raised its 2025 EPS guidance and announced cost-cutting measures expected to save $7.7 billion by the end of 2027, which boosted investor confidence in the stock.
• Despite facing declines in some products like Eliquis, Ibrance, and Prevnar, Pfizer's overall performance and future outlook seem promising, leading to the bullish market movement.
• The negative news about Trump issuing an ultimatum to pharmaceutical companies to lower drug prices did not significantly impact Pfizer's stock, as the positive earnings report overshadowed external pressures.

08.00.2025 - PFE Stock was down 2.4%

• Pfizer (PFE) experienced a strong bearish movement today.
• The market might have reacted negatively to specific news related to Pfizer, such as disappointing clinical trial results or regulatory setbacks.
• Investors could be concerned about potential challenges in Pfizer's pipeline or competitive pressures impacting its revenue outlook.
• It's essential for traders to stay updated on Pfizer's latest developments and industry trends to make informed investment decisions in the pharmaceutical sector.

29.03.2025 - PFE Stock was up 3.2%

• Pfizer exceeded Q1 earnings expectations by a substantial margin, indicating robust financial performance.
• The implementation of cost-cutting strategies has enhanced profitability, despite a drop in sales.
• Optimism among investors surrounds Pfizer's non-COVID medications driving sales growth, highlighting diversification and strength in the company's product lineup.
• The collaboration with Guardant Health for the development of new cancer treatments has likely bolstered investor confidence in Pfizer's innovative ventures, contributing to the positive market trend.

08.06.2025 - PFE Stock was up 2.2%

• Pfizer's strong bullish momentum is linked to its consistent trading performance above the 50-day average, reflecting robust positive momentum amid challenges like declines in COVID revenues and patent-related risks.
• The recent decision by the FDA chief to restrict COVID-19 vaccine approval to seniors and high-risk groups is thought to have positively influenced Pfizer's stock, considering its significant role in the vaccine market.
• Moderna's stock surge subsequent to the CDC's expanded RSV vaccine recommendations might have also played a part in the positive outlook for the pharmaceutical industry, indirectly benefiting Pfizer.
• The decrease in sales of legacy drugs for Bristol Myers (BMY) potentially underscored Pfizer's resilience and dedication to innovative products, potentially drawing investors' attention to Pfizer's stock.